<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18370" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Blepharitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eberhardt</surname>
            <given-names>Mary</given-names>
          </name>
          <aff>St Lukes University Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rammohan</surname>
            <given-names>Guhan</given-names>
          </name>
          <aff>St Luke's University Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mary Eberhardt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Guhan Rammohan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18370.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Blepharitis is an ophthalmologic condition characterized by inflammation of the eyelid margins. The diagnosis is clinical and based on irritation of the lid margins with crusting and flaking of the lashes. This activity illustrates the evaluation and treatment of blepharitis and explains the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the etiology of blepharitis.</p></list-item><list-item><p>Evaluate&#x000a0;the typical presentation of itching, burning, and crusting of eyelids in patients with blepharitis.</p></list-item><list-item><p>Identify&#x000a0;the use of warm compresses and eyelid hygiene in managing blepharitis.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration among the interprofessional team members to enhance care delivery for patients affected by blepharitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18370&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18370">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18370.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Blepharitis is an ophthalmologic condition characterized by an&#x000a0;inflammation of the eyelid margins. It can be acute or chronic, with chronic being the more common form (see <bold>Image.</bold> Illustration of Blepharitis, Swollen Eye). It can further be defined by the location of the problem, anterior versus posterior. It usually presents with recurrent symptoms that may vary over time and involve both eyes. Blepharitis is a clinical diagnosis based on irritation of the lid margins with flaking and&#x000a0;crusting of the lashes. The main treatment for blepharitis is good eyelid hygiene and elimination of triggers that&#x000a0;exacerbate symptoms. Topical antibiotics may be prescribed. Patients refractory to these measures require referral to an ophthalmologist. The goal of treatment is to alleviate symptoms. Because most blepharitis is chronic, patients must maintain a good hygiene regimen to prevent recurrences. While there is no definitive cure, the prognosis for blepharitis is good. Blepharitis is a more symptomatic condition than a true&#x000a0;health threat.<xref ref-type="bibr" rid="article-18370.r1">[1]</xref><xref ref-type="bibr" rid="article-18370.r2">[2]</xref><xref ref-type="bibr" rid="article-18370.r3">[3]</xref><xref ref-type="bibr" rid="article-18370.r4">[4]</xref></p>
      </sec>
      <sec id="article-18370.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Causes of blepharitis differ depending on whether it is an acute or chronic process and, in the case of chronic, the location of the problem. Acute blepharitis may be ulcerative or nonulcerative. An infection causes ulcerative&#x000a0;blepharitis. This is usually bacterial and, most commonly, staphylococcal. A viral etiology such as infection with <italic toggle="yes">Herpes simplex</italic> and <italic toggle="yes">Varicella zoster</italic> is also possible. Nonulcerative is usually&#x000a0;an allergic reaction such as atopic or seasonal. Its location best classifies the chronic form of blepharitis. An infection, usually staphylococcal or seborrheic disease process, is involved in anterior blepharitis. Individuals frequently have seborrheic dermatitis of the face and scalp. Also, anterior blepharitis may be associated with rosacea. Meibomian gland dysfunction causes posterior blepharitis. The glands over-secrete an oily substance, becoming clogged and engorged. Commonly, this is associated with acne rosacea, and hormonal causes are suspected. Both anterior (<italic toggle="yes">Demodex folliculorum)</italic> and posterior (<italic toggle="yes">Demodex</italic>&#x000a0;<italic toggle="yes">brevis</italic><italic toggle="yes">)&#x000a0;</italic>blepharitis may be caused by a&#x000a0;Demodex<italic toggle="yes">&#x000a0;</italic>mite. Their role is not well-established&#x000a0;since asymptomatic individuals have also&#x000a0;been found to harbor the mites at approximately the same prevalence.<xref ref-type="bibr" rid="article-18370.r5">[5]</xref><xref ref-type="bibr" rid="article-18370.r6">[6]</xref><xref ref-type="bibr" rid="article-18370.r7">[7]</xref></p>
      </sec>
      <sec id="article-18370.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Blepharitis is not specific to any group of people. It affects people of all ages, ethnicities, and gender. It is more common in individuals older than the age of 50. The total number of cases in the US at any&#x000a0;1 time is unknown. In a 2009 US survey, 37% of patients seen by an ophthalmologist and 47% of patients seen by an optometrist had signs of blepharitis. A&#x000a0;recent study carried out over 10 years&#x000a0;(2004 through 2013) in South Korea determined the overall incidence to be 1.1 per 100 person-years. This increased with time and was higher in female patients. The overall prevalence for patients over 40 years of age was 8.8%.</p>
      </sec>
      <sec id="article-18370.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathophysiology&#x000a0;of blepharitis is not&#x000a0;known. The cause is most likely multifactorial. Causative factors&#x000a0;include chronic low-grade bacterial infections of the ocular&#x000a0;surface, inflammatory skin conditions such as atopy and seborrhea, and parasitic infestations with&#x000a0;Demodex mites<italic toggle="yes">.</italic></p>
      </sec>
      <sec id="article-18370.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with blepharitis typically describe itching, burning, and crusting of the eyelids. They may experience tearing, blurred vision, and foreign body sensations. In general, symptoms tend to worsen in the morning, with crusting of the lashes being most prominent upon waking. The symptoms tend to affect both eyes and can be intermittent. The physical exam is best performed using a slit lamp. In anterior blepharitis, slit lamp exam reveals erythema and edema of the eyelid margin. Telangiectasia&#x000a0;may be present on the outer portion of the eyelid. Scaling can be seen at the base of the eyelashes, forming "collarettes." Also, loss of lashes (madarosis), depigmentation of lashes (poliosis), and misdirection of lashes&#x000a0;&#x000a0;(trichiasis)&#x000a0;may be seen. In posterior blepharitis, the meibomian&#x000a0;glands are dilated, obstructed, and may be capped with oil. Secretions from these glands may appear thick, and lid scarring may be present in the area around the glands. The tear film may show signs of rapid evaporation in all types of blepharitis. This is best evaluated by measuring&#x000a0;the tear break-up time. A slit lamp exam&#x000a0;is performed, and fluorescein&#x000a0;dye is placed in the eye. The patient is asked to blink fully and maintain an open eye for 10 seconds. The tear film is examined for breaks or dry spots under cobalt blue light. Generally, a tear break-up time of less than 10 seconds is considered abnormal.</p>
      </sec>
      <sec id="article-18370.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Blepharitis is a clinical diagnosis. No specific diagnostic testing beyond the history and physical exam is required. Individuals who fail treatment for chronic blepharitis should undergo a lid biopsy to exclude carcinoma, especially in cases of eyelash&#x000a0;loss.</p>
      </sec>
      <sec id="article-18370.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Eyelid hygiene remains the mainstay of treatment and is&#x000a0;effective in treating most cases of blepharitis. Warm, wet compresses are applied to the eye for 5 to 10 minutes to soften eyelid debris and oils and dilate meibomian glands. Immediately following this, the eyelid margins should be washed&#x000a0;gently&#x000a0;with a cotton applicator soaked in diluted baby shampoo to remove scale and debris. Care should be taken not to use too much soap since it can result in dry eyes. Individuals with posterior blepharitis benefit from a gentle massage of the eyelid margins to express oils from the meibomian glands. A cotton applicator or finger massage the lid margins in small circular patterns. During symptomatic blepharitis exacerbations, eyelid hygiene must be performed&#x000a0;2 to&#x000a0;4 times daily. In patients with chronic blepharitis, a lid-hygiene regimen&#x000a0;needs to be maintained daily for life, or irritating symptoms recur. In addition, eye makeup needs to be limited and all triggers removed. Underlying&#x000a0;conditions should be treated.<xref ref-type="bibr" rid="article-18370.r8">[8]</xref><xref ref-type="bibr" rid="article-18370.r9">[9]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="1345157">[10]</ext-link><xref ref-type="bibr" rid="article-18370.r10">[11]</xref></p>
        <p>Topical antibiotics should be&#x000a0;used in all acute and anterior blepharitis cases. They are useful in symptomatic relief and eradicating&#x000a0;bacteria from the lid margin. Topical antibiotic creams like bacitracin or erythromycin can be applied to the lid margin for 2 to 8 weeks. Oral tetracyclines and macrolide antibiotics may be used to treat posterior blepharitis that is not responsive to eyelid hygiene or is associated with rosacea. These oral antibiotics are used for their anti-inflammatory and lipid-regulating properties. Short courses of topical steroids are beneficial in patients with ocular&#x000a0;inflammation. Recent trials have shown that antibiotics and corticosteroids can significantly improve symptoms. These&#x000a0;often&#x000a0;are prescribed as a combination topical treatment in patients who have failed eyelid hygiene treatment. In patients who are felt to have significant Demodex<italic toggle="yes">&#x000a0;</italic>infestations, tea tree oil eyelid, and shampoo scrubs can be beneficial for a minimum of 6 weeks.</p>
        <p>Recent new therapies have become available for the treatment&#x000a0;of blepharitis. Thermal pulsation therapy (LipiFlow device) applies heat to anterior and posterior surfaces. Pulsations gently remove debris and crustings from the meibomian glands. MiBoFlo is a thermal therapy that is applied to the eyelids outside. BlephEx is a rotating light burr used to remove debris from meibomian gland orifices. This allows a better flow of oils and an improved response to heat therapies. The Maskin probe is a stainless steel probe applied to an anesthetized meibomian gland orifice. A light electrical current is applied to the gland to facilitate oil secretion. While some small trials have shown promise, further clinical trials&#x000a0;are needed to establish the efficacy of these treatments.</p>
      </sec>
      <sec id="article-18370.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis for blepharitis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Bacterial keratitis</p>
          </list-item>
          <list-item>
            <p>Basal cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Chalazion</p>
          </list-item>
          <list-item>
            <p>Contact lens complications</p>
          </list-item>
          <list-item>
            <p>Dry eye disease</p>
          </list-item>
          <list-item>
            <p>Epidemic keratoconjunctivitis</p>
          </list-item>
          <list-item>
            <p>Hordeolum</p>
          </list-item>
          <list-item>
            <p>Ocular rosacea</p>
          </list-item>
          <list-item>
            <p>Trichiasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18370.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>While rarely sight-threatening, blepharitis&#x000a0;can result in eyelid scarring, excessive tearing, hordeolum and chalazion formation, and chronic conjunctivitis. The development of keratitis and corneal ulcers can result in vision loss. Blepharitis is a chronic condition characterized by&#x000a0;exacerbations and remissions. While symptoms may be improved, there is rarely a cure.</p>
      </sec>
      <sec id="article-18370.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Blepharitis is managed by an interprofessional team that consists of a nurse practitioner, primary care provider, ophthalmologist, and internist. Blepharitis is characterized by an&#x000a0;inflammation of the eyelid margins, which can be acute or chronic. The main treatment for blepharitis is good eyelid hygiene and elimination of triggers that&#x000a0;exacerbate symptoms. Topical antibiotics may be prescribed. Patients refractory to these measures require referral to an ophthalmologist. The goal of treatment is to alleviate symptoms. Because most blepharitis is chronic, patients must maintain a good hygiene regimen to prevent recurrences. While there is no definitive cure, the prognosis for blepharitis is good. Blepharitis is a more symptomatic condition than a true&#x000a0;health threat. Most patients do respond to treatment, but exacerbations and remissions characterize the condition.<xref ref-type="bibr" rid="article-18370.r11">[12]</xref></p>
      </sec>
      <sec id="article-18370.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18370&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18370">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/blepharitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18370">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18370/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18370">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18370.s13">
        <fig id="article-18370.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Illustration of Blepharitis, Swollen Eye Contributed by C Rowe</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="blepharitis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18370.s14">
        <title>References</title>
        <ref id="article-18370.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huggins</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>MEN 2B masquerading as chronic blepharitis and euryblepharon.</article-title>
            <source>Orbit</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-518</page-range>
            <pub-id pub-id-type="pmid">30688132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez-Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loya-Garcia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hernandez-Quintela</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Navas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>53</fpage>
            <page-range>53-62</page-range>
            <pub-id pub-id-type="pmid">30613133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Juhasz</surname>
                <given-names>MLW</given-names>
              </name>
              <name>
                <surname>Atanaskova Mesinkovska</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Topical ketoconazole: a systematic review of current dermatological applications and future developments.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>8</issue>
            <fpage>760</fpage>
            <page-range>760-771</page-range>
            <pub-id pub-id-type="pmid">30668185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozkan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willcox</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>The Ocular Microbiome: Molecular Characterisation of a Unique and Low Microbial Environment.</article-title>
            <source>Curr Eye Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>44</volume>
            <issue>7</issue>
            <fpage>685</fpage>
            <page-range>685-694</page-range>
            <pub-id pub-id-type="pmid">30640553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ooi</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of pharmaceutical interventions for meibomian gland dysfunction: An evidence-based review of clinical trials.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>658</fpage>
            <page-range>658-668</page-range>
            <pub-id pub-id-type="pmid">30561146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soh Qin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tong Hak Tien</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Healthcare delivery in meibomian gland dysfunction and blepharitis.</article-title>
            <source>Ocul Surf</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-178</page-range>
            <pub-id pub-id-type="pmid">30458245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fromstein</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Harthan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Opitz</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title><italic>Demodex</italic> blepharitis: clinical perspectives.</article-title>
            <source>Clin Optom (Auckl)</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">30214343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pflugfelder</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Karpecki</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of blepharitis: recent clinical trials.</article-title>
            <source>Ocul Surf</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>273</fpage>
            <page-range>273-84</page-range>
            <pub-id pub-id-type="pmid">25284773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yanai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunihiro</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections.</article-title>
            <source>Drugs R D</source>
            <year>2012</year>
            <month>Dec</month>
            <day>01</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>177</fpage>
            <page-range>177-85</page-range>
            <pub-id pub-id-type="pmid">23075336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veldman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2011</year>
            <season>Fall</season>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>43</fpage>
            <page-range>43-52</page-range>
            <pub-id pub-id-type="pmid">21897139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18370.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosseini</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bourque</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Development and evaluation of a measure of patient-reported symptoms of Blepharitis.</article-title>
            <source>Health Qual Life Outcomes</source>
            <year>2018</year>
            <month>Jan</month>
            <day>11</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">29325546</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
